IN2014DN06104A - - Google Patents

Download PDF

Info

Publication number
IN2014DN06104A
IN2014DN06104A IN6104DEN2014A IN2014DN06104A IN 2014DN06104 A IN2014DN06104 A IN 2014DN06104A IN 6104DEN2014 A IN6104DEN2014 A IN 6104DEN2014A IN 2014DN06104 A IN2014DN06104 A IN 2014DN06104A
Authority
IN
India
Prior art keywords
compounds
terms
therapeutic uses
inventions relates
inventions
Prior art date
Application number
Other languages
English (en)
Inventor
Stephen Stokes
Christoper John Graham
Stuart Christopher Ray
Emma Jayne Stefaniak
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Publication of IN2014DN06104A publication Critical patent/IN2014DN06104A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN6104DEN2014 2012-01-30 2013-01-30 IN2014DN06104A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1201566.5A GB201201566D0 (en) 2012-01-30 2012-01-30 New chemical compounds
PCT/GB2013/050212 WO2013114113A1 (fr) 2012-01-30 2013-01-30 Dérivés de 1h-pyrrolo[2,3-b]pyridine et leur utilisation comme inhibiteurs de kinases

Publications (1)

Publication Number Publication Date
IN2014DN06104A true IN2014DN06104A (fr) 2015-08-14

Family

ID=45876325

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6104DEN2014 IN2014DN06104A (fr) 2012-01-30 2013-01-30

Country Status (21)

Country Link
US (3) US10000481B2 (fr)
EP (1) EP2809670B1 (fr)
JP (1) JP6199316B2 (fr)
CN (4) CN104203948A (fr)
AU (1) AU2013213954B2 (fr)
BR (1) BR112014018795B1 (fr)
CA (1) CA2862940C (fr)
DK (1) DK2809670T3 (fr)
EA (1) EA026657B1 (fr)
ES (1) ES2637340T3 (fr)
GB (1) GB201201566D0 (fr)
HK (1) HK1200447A1 (fr)
HU (1) HUE035332T2 (fr)
IL (1) IL233595B (fr)
IN (1) IN2014DN06104A (fr)
MX (1) MX352927B (fr)
NZ (1) NZ627361A (fr)
PL (1) PL2809670T3 (fr)
PT (1) PT2809670T (fr)
WO (1) WO2013114113A1 (fr)
ZA (1) ZA201405070B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
MY168958A (en) * 2012-04-23 2019-01-28 Genentech Inc Intermediates and processes for preparing compounds
CN105705499B (zh) * 2013-08-22 2018-10-12 基因泰克公司 用于制备化合物的方法
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
US10032914B2 (en) * 2015-10-20 2018-07-24 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device and manufacturing method thereof
AU2017222908B2 (en) 2016-02-23 2021-02-04 Taiho Pharmaceutical Co., Ltd. Novel condensed pyrimidine compound or salt thereof
WO2020150417A2 (fr) 2019-01-17 2020-07-23 Ifm Due, Inc. Composés et compositions pour traiter des états pathologiques associés à une activité de sting
US20230271941A1 (en) 2020-07-15 2023-08-31 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
JP2023540674A (ja) * 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための化合物および組成物
TW202216685A (zh) * 2020-07-15 2022-05-01 美商Ifm Due有限公司 用於治療與sting活性相關的病狀之化合物及組合物
WO2023137034A1 (fr) * 2022-01-12 2023-07-20 Ifm Due, Inc. Composés et compositions pour le traitement d'états associés à l'activité de sting

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012976A (en) * 1909-03-25 1911-12-26 Adolf Bordt Adding-machine.
WO2003028724A1 (fr) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Inhibiteurs de la kinase chk1
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
RU2006121990A (ru) * 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
EP2242755B1 (fr) * 2008-01-08 2012-09-12 Array Biopharma, Inc. Pyrrolopyridines en tant qu'inhibiteurs de kinase
PL2294065T3 (pl) * 2008-01-22 2014-11-28 Vernalis R&D Ltd Pochodne indolilo-pirydonu wykazujące działanie hamujące aktywność kinazy 1 punktu kontrolnego
AR071717A1 (es) * 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
CN102119162B (zh) * 2008-06-11 2014-10-08 健泰科生物技术公司 二氮杂咔唑及其使用方法
EP2461869B1 (fr) * 2009-08-06 2013-08-21 Merck Patent GmbH Nouveaux composés d'urée bicyclique
WO2011146313A1 (fr) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Composés de pyrazolopyrimidine pour le traitement du cancer
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds

Also Published As

Publication number Publication date
HUE035332T2 (en) 2018-05-02
US10000481B2 (en) 2018-06-19
MX352927B (es) 2017-12-14
NZ627361A (en) 2016-07-29
PL2809670T3 (pl) 2017-10-31
JP6199316B2 (ja) 2017-09-20
BR112014018795B1 (pt) 2020-09-29
CN106866658A (zh) 2017-06-20
WO2013114113A1 (fr) 2013-08-08
MX2014009112A (es) 2014-11-10
EA201491376A1 (ru) 2015-01-30
EP2809670A1 (fr) 2014-12-10
ES2637340T3 (es) 2017-10-11
IL233595A0 (en) 2014-08-31
PT2809670T (pt) 2017-08-23
ZA201405070B (en) 2016-03-30
CN106866658B (zh) 2021-04-27
US20180362526A1 (en) 2018-12-20
US10889582B2 (en) 2021-01-12
IL233595B (en) 2018-05-31
EA026657B1 (ru) 2017-05-31
HK1200447A1 (en) 2015-08-07
BR112014018795A2 (pt) 2017-07-04
AU2013213954A1 (en) 2014-08-07
CN111484493A (zh) 2020-08-04
CA2862940C (fr) 2021-09-14
CN107011341A (zh) 2017-08-04
DK2809670T3 (en) 2017-08-28
GB201201566D0 (en) 2012-03-14
CN104203948A (zh) 2014-12-10
US20210206762A1 (en) 2021-07-08
EP2809670B1 (fr) 2017-05-17
AU2013213954B2 (en) 2016-02-25
JP2015505555A (ja) 2015-02-23
US20150011533A1 (en) 2015-01-08
CA2862940A1 (fr) 2013-08-08

Similar Documents

Publication Publication Date Title
IN2014DN06104A (fr)
CA2900335C (fr) Analogues synthetiques d'epipolythiodioxopiperazines et leurs utilisations
HK1211467A1 (en) Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes il-15r alpha il-15r alpha il-15r alpha il-15/ il-15r alpha
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
GB201106743D0 (en) Novel compounds
MY185016A (en) Progenitor cells of mesodermal lineage
GB201106750D0 (en) Novel compounds
PH12015501083B1 (en) Novel pyridine derivatives
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MY182328A (en) Pyridine-2-amides useful as cb2 agonists
TWD158887S (zh) 粉餅盒
MX349373B (es) Nuevos derivados de pirazina.
TR201903918T4 (tr) Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
IN2015DN00085A (fr)
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
IN2015DN00962A (fr)
IN2014DN03298A (fr)
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA72478U (ru) Применение полентара как средства фригопротекторного действия
UA106373C2 (ru) Применение поллентара как средства фригопротекторного действия
UA96060C2 (ru) Применение липофлавона как средства фригопротекторного действия